Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non‐squamous non‐small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial
Authors:
- 18 May 2011
- journal article
- research article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 7 (s2) , 4-12
Abstract
Aim: The phase III AVAiL study evaluated the efficacy and safety of the anti‐vascular epidermal growth factor agent bevacizumab combined with platinum‐based chemotherapy as first‐line treatment in patients with advanced non–small‐cell lung cancer (NSCLC). We report the results of a preplanned analysis of Asian patients enrolled in AVAiL.Methods: Patients with recurrent or advanced non‐squamous NSCLC were randomized to receive bevacizumab 7.5 mg/kg, bevacizumab 15 mg/kg or placebo, plus cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles, followed by bevacizumab or placebo until disease progression. An exploratory analysis was undertaken to assess efficacy and safety in an Asian subgroup.Results: Of the 1043 patients enrolled, 105 were Asian and were included in the subgroup analysis. Progression‐free survival was 8.5 months (95% CI 7.3–10.8) in the bevacizumab 15‐mg/kg group, 8.2 (95% CI 6.6–11.7) in the 7.5‐mg/kg group and 6.1 (95% CI 5.1–8.0) in the placebo group. Median overall survival in the 7.5‐mg/kg bevacizumab group was prolonged compared with placebo group (HR 0.46; 95% CI 0.22–0.97). Nausea was the most common adverse event, occurring at similar rates (ranging from 69–76%) in all study groups. Hypertension was the most common adverse event of special interest, seen in 29, 55 and 16% of patients in the 7.5‐mg/kg and 15‐mg/kg bevacizumab and placebo groups, respectively.Conclusion: Study results strongly suggest that bevacizumab at a dose of 7.5 mg/kg improves the duration of overall survival when combined with cisplatin‐gemcitabine in Asian patients. Bevacizumab was well tolerated in this patient group.Keywords
This publication has 25 references indexed in Scilit:
- First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancerJournal of Experimental & Clinical Cancer Research, 2010
- Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status Are Independent Favorable Prognostic Factors for Overall Survival in Non-small Cell Lung Cancer: A Collaborative Epidemiologic Study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry DatabasesJournal of Thoracic Oncology, 2010
- Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Annals of Oncology, 2010
- Use of a Population-Based Cancer Registry to Calculate Twenty-Year Trends in Cancer Incidence and Mortality in Fukui PrefectureJournal of Epidemiology, 2010
- Progression-Free SurvivalThe Cancer Journal, 2009
- Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian PerspectiveJapanese Journal of Clinical Oncology, 2008
- The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future DevelopmentsThe Oncologist, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- VEGF-Targeted Therapy: Therapeutic Potential and Recent AdvancesThe Oncologist, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000